(RAY-B) RaySearch Laboratories - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000135485
RAY-B: Treatment Planning, Oncology Information, Analytics, Control
RaySearch Laboratories AB (publ) (ST:RAY-B) is a pioneering medical technology company specializing in innovative software solutions for cancer care. With a global presence spanning the Americas, Europe, Africa, the Asia-Pacific, and the Middle East, RaySearch is committed to advancing radiation therapy through its integrated suite of products. The companys offerings include RayStation, a comprehensive treatment planning system; RayCare, an oncology information system that streamlines clinical workflows; RayIntelligence, a cloud-based analytics platform for enhancing cancer therapy outcomes; and RayCommand, a treatment control system that seamlessly connects treatment machines with planning and information systems. Additionally, RayPlan supports advanced radiation therapy planning, while µ-RayStation caters to small animal irradiation research.
Founded in 1988 and headquartered in Stockholm, Sweden, RaySearch has established itself as a leader in oncology software, dedicated to improving cancer treatment through cutting-edge technology. Their solutions are integral to modern radiation oncology, facilitating precise treatment planning and efficient clinical management.
3-Month Forecast: - Technical Outlook: - The stock is trading above its 20-day (225.40) and 50-day (241.13) moving averages, indicating short-term bullish momentum. However, its below the 200-day average (193.90), suggesting a longer-term downtrend. - Average True Range (ATR) of 12.68 signals moderate volatility, implying potential price swings. - Fundamental Outlook: - High P/E (39.23) and forward P/E (31.15) reflect strong growth expectations, driven by continued demand for advanced oncology solutions. - Elevated P/B (9.11) and P/S (6.70) ratios indicate investor confidence in future growth, supported by a robust return on equity (RoE) of 23.21%. - Projection: - Short-term gains are anticipated as the companys strong fundamentals and product pipeline align with market demand. However, investors should monitor volume trends and moving average crossovers to confirm the uptrends sustainability.Additional Sources for RAY-B Stock
RAY-B Stock Overview
Market Cap in USD | 826m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception |
RAY-B Stock Ratings
Growth Rating | 69.4 |
Fundamental | 81.0 |
Dividend Rating | 9.85 |
Rel. Strength | 116 |
Analysts | - |
Fair Price Momentum | 263.13 SEK |
Fair Price DCF | 72.29 SEK |
RAY-B Dividends
Dividend Yield 12m | 0.61% |
Yield on Cost 5y | 1.89% |
Annual Growth 5y | % |
Payout Consistency | 17.2% |
RAY-B Growth Ratios
Growth Correlation 3m | -47.7% |
Growth Correlation 12m | 92.5% |
Growth Correlation 5y | 46.2% |
CAGR 5y | 30.49% |
CAGR/Max DD 5y | 0.50 |
Sharpe Ratio 12m | 0.54 |
Alpha | 101.66 |
Beta | 1.411 |
Volatility | 38.71% |
Current Volume | 147.3k |
Average Volume 20d | 82k |
As of May 05, 2025, the stock is trading at SEK 262.00 with a total of 147,311 shares traded.
Over the past week, the price has changed by +5.65%, over one month by +23.88%, over three months by +3.97% and over the past year by +114.57%.
Yes, based on ValueRay Fundamental Analyses, RaySearch Laboratories (ST:RAY-B) is currently (May 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 81.02 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RAY-B as of May 2025 is 263.13. This means that RAY-B is currently overvalued and has a potential downside of 0.43%.
RaySearch Laboratories has no consensus analysts rating.
According to ValueRays Forecast Model, RAY-B RaySearch Laboratories will be worth about 315.8 in May 2026. The stock is currently trading at 262.00. This means that the stock has a potential upside of +20.52%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 330 | 26% |
Analysts Target Price | - | - |
ValueRay Target Price | 315.8 | 20.5% |